原发性肝癌诊断中血清α-L-岩藻糖苷酶的价值

The value of serum α-L-fucosidase activity in the diagnosis of primary liver cancer

目的 探讨血清α L 岩藻糖苷酶 (AFU)在原发性肝癌诊断中的应用价值。方法 设定原发性肝癌组、继发性肝癌组、肝硬化组、正常对照组 ,比较各组测定的AFU水平 ;在原发性肝癌组中做血清AFU水平与TNM分期相关性分析并统计AFU及AFP阳性率 ;比较接受有效治疗前后原发性肝癌患者AFU水平的变化。结果 原发性肝癌组与其他各组比较 ,AFU差异均有显著性 (P <0 .0 5 )。血清AFU水平与原发性肝癌TNM分期呈正相关 (P <0 .0 0 1) ,其中AFU阳性率 76 .6 % ,AFP阳性率6 4.5 % ,同时测定阳性检出率可达 86 .2 %。 36例经过有效治疗的原发性肝癌AFU值有显著性下降(P <0 .0 0 5 )。结论 AFU敏感性较高 ,与AFP协同应用将增加阳性检出率。有助于原发性肝癌的诊断、判断病情变化及治疗效果。

Objective To analyse the value of serum α L fucosidase (AFU) in the diagnosis of primary liver cancer (PLC). Methods Serum AFU was studied in 141 patients with PLC, 17 patients with secondary liver cancer, 16 patients with cirrhosis, and 30 controls. Rank correlation analysis was used to assess the relation between value of AFU activity and TNM staging. The results were compared to those of serum AFP determination. Results AFU was incresed in 108 of 141 (76.6%) patients. The positive rate was statistically different from that in patients with secondary liver cancer, cirrhosis, and that in normal individual. The AFU level was correlated with TNM stage. In 25 PLC patients with AFU>500 nmol·L -1 ·S -1 , the average survival time was only 71 days. In 36 PLC patients who had received effective treatment, the serum AFU decreased to a significantly lower level than that examined before treatment. The positive rate of AFP in PLC patients was 64.5%. It rose to 86.2% if both parameters were used.Conclusion AFU is a useful marker of PLC for diagnosis and posttreatment monitoring. Subject